一个血液透析患者患有凝血因子XI和因子XII缺乏症的病例报告
Xueying Li1,2, Yong Wang3
1Department of Nephrology, Hospital of University of Traditional Chinese Medicine, Chengdu, China.
Seminars in dialysis
|August 18, 2024
概括
患有XI因子和XII因子缺乏症的患者在血液透析期间可能需要较低的抗凝剂剂量. 仔细监测允许安全使用低分子量肝素 (LMWHs),即使有出血风险.
科学领域:
- 血液学 血液学 血液学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 血管生物学 血管生物学
背景情况:
- 凝血因子XI (FXI) 和因子XII (FXII) 的缺陷是罕见的遗传性疾病.
- 这两种缺陷都会延长激活的部分血栓塑时间,并损害血栓形成,使血液透析抗凝过程复杂化.
- 标准抗凝剂,如氨酸和低分子量氨酸 (LMWHs) 往往是避免在患有出血风险的患者.
研究的目的:
- 报告 FXI 和 FXII 综合缺陷患者成功进行血液透析的病例.
- 评估LMWHs作为这种特定患者群体中的抗凝策略的安全性和有效性.
- 要突出由于FXI/FXII缺陷固有的抗凝剂效应导致抗凝剂剂量降低的潜力.
主要方法:
- 一个68岁的女性患者的病例报告,患有结合的FXI和FXII缺陷,正在接受血液透析.
- 使用精心监测的低剂量LMWHs来管理抗凝药.
- 评估了临床结果和抗凝血参数.
主要成果:
- 患者成功完成了用LMWH抗凝剂进行的血液透析.
- 结合的FXI和FXII缺陷似乎产生了抗凝剂作用,使LMWH剂量减少.
- 在治疗期间没有报告任何不良出血事件.
结论:
- 结合的FXI和FXII缺陷具有固有的抗凝性质,可以影响血液透析期间的抗凝管理.
- 在密切的临床和实验室监测下,低剂量LMWH治疗可能是血液透析患者具有这些缺陷的可行和安全的抗凝选择.
- 这一案例表明,考虑到因子缺陷的个性化抗凝策略对于风险人群的血液透析管理至关重要.
相关概念视频
01:24Disorders of Hemostasis
758
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
758
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
654
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
654
01:20Extrinsic and Intrinsic Pathways of Hemostasis
6.6K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
6.6K
01:09Coagulation
5.7K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
5.7K